Alkermes’ ALKS 5461 medication gets FDA Fast Track status for main depressive disorder Alkermes plc today announced that the U.S. Meals and Drug Administration offers granted Fast Track position for ALKS 5461 for the adjunctive treatment of major depressive disorder in sufferers with an inadequate response to regular therapies more . Fast Monitor is a process designed to facilitate the development, and expedite the overview of drugs to take care of serious conditions and with the potential to handle an unmet medical need.
Related StoriesNew UCL study highlights genes connected with schizophrenia and obesityResearchers examine neuroanatomical signature of schizophrenia in various ethnic groupsVraylar capsules right now accepted by FDA to treat schizophrenia, bipolar disorder in adults Enrollment was completed carrying out a prespecified interim evaluation of sample size. The study continues to be blinded until completion. There exists a apparent and compelling dependence on long-acting injectable medications for sufferers with schizophrenia, stated Elliot Ehrich, M.D., Chief Medical Officer of Alkermes. We are excited to full enrollment in this cautiously conducted, multinational study and appearance forwards to reporting the outcomes in the first fifty % of 2014.